Antiviral Res
Abstract
Nipah virus (NiV) continues to cause outbreaks of fatal human encephalitis due to spillover from its bat reservoir. We determined that a single dose of replication-defective vesicular stomatitis virus (VSV)-based vaccine vectors expressing either the NiV fusion (F) or attachment (G) glycoproteins protected hamsters from over 1000 times LD50 NiV challenge. This highly effective single-dose protection coupled with an enhanced safety profile makes these candidates ideal for potential use in livestock and humans.CC999999/Intramural CDC HHS/United StatesT32 AI007610/AI/NIAID NIH HHS/United StatesU54 AI057158/AI/NIAID NIH HHS/United StatesU54-AI057158/AI/NIAID NIH HHS/United States2015-01-01T00:00:00Z24184127PMC38748897469vault:2352- Article
- Henipavirus
- Nipah
- vaccine
- VSV
- single-dose
- hamster
- glycoproteins
- Animals
- Cricetinae
- Disease Models, Animal
- Drug Carriers
- Henipavirus Infections
- Mesocricetus
- Nipah Virus
- Survival Analysis
- Vaccines, Synthetic
- Vesiculovirus
- Viral Structural Proteins
- Viral Vaccines
- Article
- Henipavirus
- Nipah
- vaccine
- VSV
- single-dose
- hamster
- glycoproteins
- Animals
- Cricetinae
- Disease Models, Animal
- Drug Carriers
- Henipavirus Infections
- Mesocricetus
- Nipah Virus
- Survival Analysis
- Vaccines, Synthetic
- Vesiculovirus
- Viral Structural Proteins
- Viral Vaccines
Similar works
This paper was published in CDC Stacks.
Having an issue?
Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.